We present the case of a 58 year old woman, who achieved complete response taneous melanoma metastasis after treatment with ipilimumab at 3 mg/Kg. The was given dacarbazine as a first line treatment for her cutaneous metastasis and response was achieved. However, after 26 cycles of chemotherapy, the cutaneous progressed, so ipilimumab was chosen as a second line treatment. The patient ble for the compassionate use of ipilimumab.Two weeks after the fourth ipilimumab, a complete response of most cutaneous metastasis was noted, with response of the remaining lesions, which were still regressing at the last follow-Ipilimumab, which was recently reported to improve survival in patients with melanoma, represents a most promising immunotherapeutic drug and it has proved for patients with advanced melanoma as a first- and second-line treatment FDA and as a second-line treatment by the European Medicines Agency (EMA).
The incidence of melanoma is increasing worldwide. Prognosis for metastatic melanoma is poor; early detection of recurrent or metastatic disease may improve therapy strategies and survival. Several possible biomarkers for melanoma have been investigated. S-100B was found to be a sensitive and specific serological tumor marker; furthermore, its con-centrations are correlated with the clinical stage of disease. Serum S-100B is also an inde-pendent prognostic factor for survival and can be used to monitor response to treatment. We present the case of a 55 year old woman, whose diagnosis of melanoma distant me-tastases was suggested by a progressive increase in serum S-100B levels, while other blood tests, physical exam and imaging techniques, including PET/TC and CT-scan, were negative. S-100B is currently the most accurate biomarker in melanoma patients; its role in the management of melanoma patients has been the object of study and it has been documented as a valuable independent prognostic factor. The case we present shows that S-100B levels may also be useful in the early detection of melanoma recurrences, even when imaging techniques are negative.
We describe the case of a 42 year old woman who presented malignant melanoma on an 8-cm acquired speckled lentiginous nevus on the inferior part of her leg. Although melanoma arising in speckled lentiginous nevus is a rare occurrence, dermatologists and plastic surgeons need to be aware that it may occur.